Tri-Luma Cream Available Again for Melasma

Galderma announced that Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) cream is available again for short-term treatment (up to 8 weeks) of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens.

Tri-Luma cream is a triple combination product that contains fluocinolone acetonide, a mild corticosteroid to reduce inflammation; hydroquinone, a de-pigmenting agent that interrupts the formation and synthesis of melanin; and tretinoin, a retinoid to increase skin cell turnover rate for skin exfoliation.